Department of Health and Social Care<p>Up to 50% of cancer patients enrolled in the 100,000 genomes project, including patients with blood cancer, have seen a change in their treatment since receiving their result. This could be eligibility for a new trial, or prescription of a new medicine.</p><p>The National Genomic Test Directory outlines the range of genomic tests – from whole genomic sequencing to tests for single genes and molecular markers – that are available as part of the National Health Service clinical service.</p><p>From summer 2019, whole genome sequencing will be implemented as part of routine clinical care and be available to:</p><p>- Seriously ill children with a suspected genetic disorder, including those with cancer;</p><p>- People with one of 21 rare and inherited conditions; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using whole genome sequencing – children with cancer, sarcoma and acute myeloid leukaemia.</p>GosportCaroline Dinenage2019-05-09false2019-05-09T14:31:31.08Z17Health and Social CareHealth and Social Care2019-04-30Haematological Cancer: Screening1House of CommonsTo ask the Secretary of State for Health and Social Care, what his timetable is for whole genome sequencing to be made available to patients with blood cancer; and what assessment he has made of the potential benefits of that sequencing for those patients' care.falseCrawleyHenry Smith24926110011